LON:AGY Allergy Therapeutics (AGY) Share Price, News & Analysis GBX 5 +0.25 (+5.26%) As of 09/15/2026 07:05 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarnings About Allergy Therapeutics Stock (LON:AGY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Allergy Therapeutics alerts:Sign Up Key Stats Today's Range 4.52▼ 550-Day Range 4.70▼ 7.4052-Week Range 4.50▼ 12.10Volume254,682 shsAverage Volume375,454 shsMarket Capitalization£316.63 millionP/E RatioN/ADividend Yield8.33%Price TargetN/AConsensus RatingN/A Company Overview Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development. Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group has achieved over 9% compound annual growth since formation and employs c.500 employees. Read More Receive AGY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allergy Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AGY Stock News HeadlinesAllergy Therapeutics PlcJune 25, 2026 | fool.comAllergy Therapeutics agrees new debt fundingFebruary 24, 2026 | finance.yahoo.com“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI company holding 150 patents for technology that processes information up to 1,000 times faster than standard AI. Wall Street projects the company's sales to more than triple in the coming year, and Brown notes it's roughly the same size Nvidia was a decade ago, with a key catalyst set for November 11. | Brownstone Research (Ad)GSK grabs RAPT for $2.2B in big bet on food allergy drugsJanuary 21, 2026 | msn.comGSK digs in on allergies with $2.2 billion Rapt Therapeutics buyoutJanuary 20, 2026 | msn.comAllergy Therapeutics reports 7% revenue growth in first halfJanuary 19, 2026 | in.investing.comAllergy Therapeutics plc (AGY.L) - Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comSMALL CAP IDEA: Allergy Therapeutics transformation has redefined its trajectoryDecember 23, 2024 | msn.comSee More Headlines AGY Stock Analysis - Frequently Asked Questions How have AGY shares performed this year? Allergy Therapeutics' stock was trading at GBX 11.20 at the beginning of 2026. Since then, AGY stock has decreased by 55.4% and is now trading at GBX 5. How were Allergy Therapeutics' earnings last quarter? Allergy Therapeutics plc (LON:AGY) issued its quarterly earnings data on Tuesday, March, 31st. The company reported ($0.38) earnings per share (EPS) for the quarter. The business earned $36.28 million during the quarter. Allergy Therapeutics had a positive trailing twelve-month return on equity of 409.00% and a negative net margin of 85.46%. How do I buy shares of Allergy Therapeutics? Shares of AGY stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Allergy Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Allergy Therapeutics investors own include Royalty Pharma (RPRX), genedrive (GDR), Intel (INTC), IQE (IQE), AstraZeneca (AZN) and Babcock International Group (BAB). Company Calendar Last Earnings3/31/2026Today9/16/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolLON:AGY CIKN/A Webwww.allergytherapeutics.com Phone+44-1903-844700FaxN/AEmployees612Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth-30.7Net Income-£52.59 million Net Margins-85.46% Pretax MarginN/A Return on Equity409.00% Return on Assets-34.76% Debt Debt-to-Equity Ratio629.58 Current Ratio1.13 Quick Ratio1.48 Sales & Book Value Annual Sales£57.29 million Price / Sales5.53 Cash FlowGBX 1.37 per share Price / Cash Flow3.66 Book ValueGBX 0.10 per share Price / Book50.67Miscellaneous Outstanding Shares6,332,530,000Free FloatN/AMarket Cap£316.63 million OptionableNot Optionable Beta0.84 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (LON:AGY) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our PartnersJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...Banyan Hill Publishing | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allergy Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Allergy Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
